Latest News and Press Releases

STOCKHOLM, Sweden, May 02, 2005 (PRIMEZONE) -- First quarter 2005 Acquisition of Cibacen and Cibadrex, pharmaceuticals from Novartis, enhanced sales and profit. -- Group sales jumped 45%...

STOCKHOLM, Sweden, July 2, 2004 (PRIMEZONE) -- Meda has signed an agreement with the Belgian pharmaceuticals company Omega Pharma to acquire the European rights to the tablet formulations of the...

STOCKHOLM, Sweden, April 16, 2003 (PRIMEZONE) -- Meda (Other OTC:MDABF) (Stockholm:MEDAa) announces that the company has acquired the rights in the U.K. and Sweden to the well-known analgesic drug...

STOCKHOLM, Sweden, Nov. 18, 2002 (PRIMEZONE) -- Meda AB (Other OTC:MDABF) (Stockholm:MEDAa), the Swedish Specialty Pharmaceutical Company, has agreed to a deal with the GlaxoSmithKline Group (GSK) on...

STOCKHOLM, Sweden, Sept. 12, 2002 (PRIMEZONE) -- Meda has signed a long-term license agreement with Vivus for the exclusive marketing rights of MUSE(R) (alprostadil) in Europe. VIVUS markets MUSE in...

STOCKHOLM, Sweden, July 01, 2002 (PRIMEZONE) -- Meda has signed an agreement with Karolinska Innovation AB regarding acquisition of patents based upon Professor Lars Burmans discovery that the toxin...

STOCKHOLM, Sweden, June 19, 2002 (PRIMEZONE) -- Meda has signed a long-term license agreement with the pharmaceutical company Tedec-Meiji concerning the exclusive rights to the product Adant...

STOCKHOLM, Sweden, May 22, 2002 (PRIMEZONE) -- Meda has entered into a long-term strategic agreement with India's largest pharmaceutical company, Ranbaxy Laboratories Limited, regarding generic...

STOCKHOLM, Sweden, Feb. 12, 2002 (PRIMEZONE) -- Meda has concluded a long-term license agreement with the European pharmaceuticals group Recordati on sole marketing rights to Zanidip (lercanidipin)...